Arjun V. Balar, MD
Associate Professor of Medicine, Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU – Langone Health
New York, NY
This patient-centric activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy.
This initiative is designed for patients with cancer who are treated or eligible for treatment with immunotherapy.
Upon completion of the program, attendees should be able to:
- Discuss the role of immunotherapy through immune checkpoint inhibition in the spectrum of cancer treatment
- Examine the potential immune-related adverse events (irAEs) of immune checkpoint inhibition, including symptomatology and management across multiple grades of irAEs
- Describe the role of the patient in the timely irAE recognition, identification and management
- Explain how shared-decision making (SDM) can help foster a patient-centered approach to cancer care and survivorship
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Dr. Arjun Balar discloses that he is a consultant with AstraZeneca/Medimmune; Genentech, Inc./F. Hoffmann La Roche Ltd.; Merck & Co., Inc., Incyte Inc, Pfizer and Seattle Genetics.
The independent reviewers, staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:
Staff, Planners and Managers
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Russie Allen, Outcomes Coordinator for Med Learning Group has nothing to disclose.
Randall Higgins, PharmD, Medical Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Melissa A Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: January 28, 2021
EXPIRATION DATE: January 28, 2022
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited